PremiumThe FlyWilliam Blair healthcare analysts hold an analyst/industry conference call Promising Developments in Axsome Therapeutics’ AXS-12 Bolster Buy Rating Reddit initiated, Roku upgraded: Wall Street’s top analyst calls PremiumThe FlyBofA says Phase 3 MDD trial miss has ‘no impact’ on Axsome price target Axsome Therapeutics: Strategic Initiatives and Growth Potential Justify Buy Rating Despite PARADIGM Study Setback Axsome selloff on study miss should be ‘contained,’ says Mizuho PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Mizuho ups Axsome target, calls selloff on data ‘misplaced’ Positive Outlook on Axsome Therapeutics Despite Modest Market Reaction 
